Q3 Results 2025: Vedanta profit surges 70.01%; Pfizer profit down 1.83%

Pfizer Ltd on Friday released its fiscal third quarter earnings report with profit at Rs 127.60 crore, posting a drop of 1.83 per cent in comparison to Rs 129.98 crore during the same period of previous financial year. It posted Q3 revenue from operations at Rs 537.99 crore, marginally lower than Rs 539.97 crore during the third quarter of FY24. The company EBITDA stood at Rs 146 crore, down 4.4 per cent YoY.

Godrej Agrovet Ltd on Friday released its fiscal third quarter earnings report with profit at Rs 109.85 crore, up 32.41 per cent in comparison to Rs 82.96 crore during the corresponding quarter of FY24. It posted revenue from operations at Rs 2449.63 crore, reporting a growth of 4.45 per cent as against Rs 2345.21 crore during the third quarter of previous financial year. The company EBITDA was up 38.4 per cent YoY at Rs 220 crore.

Jai Shroff, Chairman and Group CEO, said, “We are seeing strong bounce back versus last year, with normalization of business, and recovery of volumes and prices. This has helped in regaining our contribution margins back to our previous higher levels. Through strong focus, the team has done a commendable job in bringing down the working capital, resulting in a significant reduction of our net debt versus September, 2024. With this strong performance, we are confident of delivering our EBITDA and free cash flow guidance for the full year.”

Consolidated R&D investments were at Rs 845.0 crore for Q3FY25 or 6.3 per cent of sales as compared to Rs 824.50 crore for Q3 last year. For the first nine months, R&D expense was Rs. 2431.90 crore, or 6.2 per cent of sales. “Our R&D efforts span across both specialty and generic businesses and we continue to invest in building the pipeline for various markets including the US, Emerging Markets, RoW Markets and for India. We have a comprehensive product offering in the US market consisting of approved ANDAs for 541 products while filings for 109 ANDAs await US FDA approval, including 28 tentative approvals. Additionally, the portfolio includes 51 approved NDAs while 13 NDAs await US FDA approval. For the quarter, 6 ANDA were filed and 2 ANDA approvals were received,” the company said.

Sun Pharma declared an interim dividend of Rs 10.50 per equity share of Re 1 each of the company for the financial year 2024-25. “As intimated on January 16, 2025, the Record Date for entitlement of interim dividend for the financial year 2024-25 is February 06, 2025. The interim dividend shall be paid on or before February 20, 2025,” it said in a regulatory filing.

Ajay Goel, CFO, Vedanta, said, “This quarter marks a stellar performance, delivering the highest Q3 EBITDA of Rs 11,284 crore, a remarkable 30% growth year-on-year, with a robust EBITDA margin of 34%. Our PAT stood at Rs 4,876 crore, reflecting an exceptional 70% YoY growth, showcasing the resilience of our business. This success has been driven by our focus on cost efficiencies, volume growth, and favourable commodity prices. The recent upgrade in our credit rating, along with a leverage improvement to 1.4x, highlights our financial strength and the market’s confidence in Vedanta’s growth trajectory.”

Vedanta Limited on Friday released its fiscal third quarter earnings report with profit at Rs 4,876 crore, reporting a growth of 70.01 per cent in comparison to Rs 2,868 crore during the same period of previous financial year. It posted revenue from operations at Rs 38,526 crore, up 10.18 per cent as against Rs 34,968 crore during the same period last year. The company recorded its highest ever third quarter EBITDA at Rs 11,284 crore, up 30 per cent YoY.

Marico Ltd on Friday released its fiscal third quarter earnings report with profit at Rs 399 crore, up 4.18 per cent in comparison to Rs 383 crore recorded during the same period of previous financial year. It posted revenue from operations at Rs 2,794 crore, reporting a growth of 15.36 per cent as against Rs 2,422 crore during the third quarter of FY24. The company recorded underlying volume growth of 6 per cent in the India business and constant currency growth of 16 per cent in the international business. Consolidated and domestic revenue growth, as well as underlying volume growth in the India business, stood at a 13-quarter high. The company EBITDA stood at Rs 533 crore.

Punjab National Bank on Friday released its fiscal third quarter earnings report with profit at Rs 4508.21 crore, posting a jump of 102.82 per cent in comparison to Rs 2222.81 crore during the same quarter of FY24. The total income for the quarter in review stood at Rs 34,751.70 crore, up 15.99 per cent as against Rs 29,961.65 crore during the third quarter of previous fiscal year. Net Interest Income (NII) stood at Rs 11,032.2 crore.

• E-commerce: Acceleration aided by quick commerce, consumer acquisition, festival activation and premiumization. Kitkat, Nescafé, Maggi further fuelled growth.

• Organized Trade: Retail business continued its growth journey led by Maggi noodles, beverages and overall premiumization.

• Out of Home (OOH): One of the fastest growing businesses driven by continued portfolio transformation and premiumization, robust customer acquisition and geographical expansion beyond metros and mega cities. Expanded presence with Nestlé Retail One Kiosks to 940+ across colleges, hospitals, and tourist hotspots.

• Export: Registered strong growth across key international markets powered by nutrition, Instant Tea and confectionery while the coffees export continued to sustain double-digit growth. Nestlé Munch, Nescafé Sunrise, Maggi Masala-Ae-Magic were extended to new markets in the United States and the United Arab Emirates.

Nestle India Ltd on Friday released its fiscal third quarter earnings report with profit at Rs 688.01 crore, posting a growth of 4.94 per cent in comparison to Rs 655.61 crore during the corresponding quarter of FY24. It reported revenue from operations at Rs 4779.73 crore, up 3.90 per cent as against Rs 4600.42 crore during the same period of previous financial year.

Elara Securities said, “While Shree Cement (SRCM) lagged peers, UltraTech Cement (UTCEM IN) and Ambuja Cements (ACEM IN) in terms of volume performance, reporting ~1% YoY drop, its QoQ EBITDA/tonne growth of ~Rs 300 outpaced UTCEM’s Rs 226 rise and ACEM’s Rs 243 dip. SRCM has re-emerged as a margin leader in the cement industry with EBITDA/tonne of Rs 1,079, due to higher exposure to North India and lower power and fuel cost. With new capacity expected to come on stream in Q1FY26 and base turning favorable from Q2FY26, we believe volume underperformance by SRCM is unlikely to continue in the long term. Further, most of the capex cost continues to be lower than the acquisition cost for peers, which should enable it to earn a better ROCE than peers with a lean balance sheet. Also, SRCM’s capacity is likely to remain more skewed to North India, where utilization is expected to be higher than pan-India average.”

Net R&D investments for the quarter were at Rs 199 crore, representing 7% of revenue ex-Syngene.

Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, “The Biocon Group reported Q3FY25 Operating Revenue of Rs 3,821 crore, with performance driven by a sustained double-digit growth of 14% on a like-for-like basis in Biosimilars and a return to growth in Research services, which grew by 11%. The growth trajectory is clearly visible with sequential growth across all the three business segments this quarter. EBITDA at Rs 787 crore, reported a growth of 16% while Profit before Tax and Exceptional Items at Rs 138 crore, improved significantly from a marginal loss last year, on a like-for-like basis. Syngene’s return to growth, combined with global approvals for bUstekinumab and European approval for gLiraglutide, will pave the way for launches and drive growth in Q4 and beyond. These developments will strategically position the Biocon Group for enhanced long-term growth.”

JM Financial said, “We believe BAF is one of the only few large cap companies across our financials coverage which will grow 20%+ over the couple of years (25% CAGR over FY24-27E) with healthy profitability (avg RoA/RoE of 4.1%/21% over FY25-27E). Moreover, it was the first company to proactively identify current stress in unsecured segments and therefore cut down its exposure to these segments (currently nil exposure to MFI loans). We believe the current valuations at 23x FY26e/18x FY27e EPS offers an attractive opportunity given its strong RoA/RoE profile and ability to grow across cycles. We roll forward our estimates to FY27E and expect earnings CAGR of 25% over FY24- 27E with consistent 4%+ RoAs and 20%+ RoEs.”